Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) announced changes to a blockbuster November 2015 deal that had granted Sanofi (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to three diabetes treatments in Hanmi's "Quantum Project" portfolio. Hanmi will return EUR 196 million ($204.8 million) of the deal's original EUR 400 million upfront payment, Sanofi spokesperson Mai Tran told BioCentury.
Tran said Sanofi will continue to lead development of one of the programs, efpeglenatide (LAPS CA Exendin-4), a glucagon-like peptide-1 receptor (GLP-1R; GLP1R) agonist. Hanmi will reassume development of once-weekly insulin analog LAPS Insulin 115, as well as LAPS Insulin Combo, which includes LAPS Insulin 115 and efpeglenatide. Sanofi will take over development of the LAPS Insulin Combo after an undisclosed period...
BCIQ Target Profiles